Ignite Creation Date:
2025-12-24 @ 11:30 PM
Ignite Modification Date:
2026-02-25 @ 7:28 PM
Study NCT ID:
NCT02951156
Status:
TERMINATED
Last Update Posted:
2020-12-17
First Post:
2016-10-19
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Sponsor:
Pfizer
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
B9991011
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |